Patrick TricoliCEO, ReST Therapeutics
Patrick Tricoli is the CEO of ReST Therapeutics, bringing a wealth of experience and strategic vision to the company.
Prior to this role, Patrick was the CEO of Nanobiotix Corp., the US affiliate of Nanobiotix based in Cambridge, MA. Since joining Nanobiotix in 2014, he has played a pivotal role in establishing and expanding the company's presence in the United States. As the Global Head of Business Development, Patrick has been instrumental in shaping and executing Nanobiotix's partnering strategy, leading to impactful collaborations and successful deal negotiations worth over $2 billion.
Patrick's career in the pharmaceutical industry is marked by significant achievements. At Sanofi, he held key leadership positions, including Global Head of Partnering and Innovation R&D, and Head of External Innovation Europe. During his tenure at Sanofi, Patrick guided multiple teams across Europe, Asia, and the U.S., developing robust international relationships, formulating global business strategies, and establishing collaborative R&D teams. His research focus on neurosciences began earlier in his career, during his time in pharmaceutical R&D at Lederle and Synthelabo from 1989 to 1995.
Patrick serves on the board of Naya Biosciences and acts as a Strategy & Corporate Development Advisor for NanOlogy.
In addition to his corporate roles, Patrick has been serving as a Foreign Trade Advisor for New England on behalf of the French government since 2017. In this capacity, he contributes to the economic and trade initiatives between France and the United States, further extending his influence in the international arena.
Patrick holds a PharmD and a master’s degree in pharmacology and pharmacokinetics, as well as an Executive MBA from ESCP Europe.